Details of the Drug

General Information of Drug (ID: DMF28YC)

Drug Name

Atorvastatin

Synonyms

Atogal; Atorlip; Atorpic; Atorvastatina; Atorvastatine; Atorvastatinium; Atrovastin; Cardyl; Faboxim; Lipotropic; Lipovastatinklonal; Liprimar; Lowden; Sincol; Sortis; Sotis; Torvacard; Torvast; Totalip; Tozalip; Tulip; Vastina; Xanator; Xarator; Xavator; Zurinel; Atorvastatin (INN); Atorvastatin [INN:BAN]; Lipitor (TN); Lipitor(TM); Sortis (TN); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1]
Angina pectoris	BA40	Approved	[1]
Arteriosclerosis	BD40	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Approved	[2]
Coronary atherosclerosis	N.A.	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[1]
Hyperlipidemia	5C80.Z	Approved	[3]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[1]
Hypertriglyceridemia	5C80.1	Approved	[1]
Inflammation	1A00-CA43.1	Approved	[1]
Non-insulin dependent diabetes	5A11	Approved	[1]
Psoriasis	EA90	Approved	[1]
Type-1/2 diabetes	5A10-5A11	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Stroke	8B20	Investigative	[1]
Venous thromboembolism	BD72	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticholesteremic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

558.6

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [5]
Elimination: 1% of drug is excreted from urine in the unchanged form [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.04573 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0204 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Acute myocardial infarction	Not Available	MMP3	OTGBI74Z	[7]
Arteriosclerosis	Not Available	CES1	OT9L0LR8	[7]
-----------

Chemical Identifiers

Formula: C33H35FN2O5
IUPAC Name: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
Canonical SMILES: CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
InChI: InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
InChIKey: XUKUURHRXDUEBC-KAYWLYCHSA-N

Cross-matching ID

PubChem CID: 60823
ChEBI ID: CHEBI:39548
CAS Number: 134523-00-5
DrugBank ID: DB01076
TTD ID: D01QIN
VARIDT ID: DR00030
INTEDE ID: DR0155
ACDINA ID: D00050

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[8]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)	TTDJB68	.	Inhibitor	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[10]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[12]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[13]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[14]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[15]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[17]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[18]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[19]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[20]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[21]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[22]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[23]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	OT7TNF0L	AAPK1_HUMAN	Gene/Protein Processing	[24]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[25]
Angiopoietin-2 (ANGPT2)	OTEQK65P	ANGP2_HUMAN	Gene/Protein Processing	[26]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Gene/Protein Processing	[27]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Gene/Protein Processing	[28]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[29]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[30]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Gene/Protein Processing	[31]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Regulation of Drug Effects	[32]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acute coronary syndrome

ICD Disease Classification

BA41

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
HMG-CoA reductase (HMGCR)	DTT	HMGCR	1.01E-05	0.65	1.53
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.29E-14	-7.08E-01	-1.99E+00
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTP	OATP2B1	3.80E-01	-1.23E-02	-5.33E-02
Monocarboxylate transporter 2 (SLC16A7)	DTP	MCT2	4.57E-02	2.44E-01	5.98E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTP	OATP1A2	7.28E-02	-7.13E-02	-4.55E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	1.65E-01	-6.07E-02	-3.77E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	3.27E-01	-5.78E-02	-3.84E-01
Monocarboxylate transporter 1 (SLC16A1)	DTP	MCT1	1.39E-04	6.49E-01	2.64E+00
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	2.00E-01	5.79E-02	3.00E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.47E-02	-1.13E-01	-1.13E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.65E-02	-8.90E-02	-5.58E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.24E-05	-3.48E-01	-1.34E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Atorvastatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Atorvastatin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[33]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Atorvastatin caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[34]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[35]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[36]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Atorvastatin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[34]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[33]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Atorvastatin due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[35]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Atorvastatin due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[35]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Atorvastatin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[37]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Atorvastatin caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[37]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Atorvastatin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[38]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Atorvastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[39]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Atorvastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Atorvastatin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[40]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[33]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[41]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Atorvastatin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[42]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[43]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Atorvastatin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Esterified estrogens	DM9KZDO	Minor	Decreased metabolism of Atorvastatin caused by Esterified estrogens mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Atorvastatin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Atorvastatin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
Quinestrol	DMJ6H1Z	Minor	Decreased metabolism of Atorvastatin caused by Quinestrol mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Anisindione	DM2C48U	Minor	Increased risk of bleeding by the combination of Atorvastatin and Anisindione.	Coagulation defect [3B10]	[44]
Drospirenone	DM1A9W3	Minor	Decreased metabolism of Atorvastatin caused by Drospirenone mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[44]
Levonorgestrel	DM1DP7T	Minor	Decreased metabolism of Atorvastatin caused by Levonorgestrel mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[44]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Atorvastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[37]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Atorvastatin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[45]
MK-8228	DMOB58Q	Major	Decreased clearance of Atorvastatin due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[46]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Atorvastatin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[47]
[3H]estrone-3-sulphate	DMGPF0N	Minor	Decreased metabolism of Atorvastatin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme.	Discovery agent [N.A.]	[44]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Atorvastatin caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Atorvastatin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[48]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Atorvastatin caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Atorvastatin caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[35]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Atorvastatin caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Atorvastatin caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Atorvastatin and Cannabidiol.	Epileptic encephalopathy [8A62]	[35]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Atorvastatin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[34]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Atorvastatin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[49]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Atorvastatin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[35]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Atorvastatin caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[34]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Atorvastatin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[50]
Simeprevir	DMLUA9D	Major	Decreased metabolism of Atorvastatin caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[51]
Telaprevir	DMMRV29	Major	Decreased metabolism of Atorvastatin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[52]
GS-9857	DMYU6P5	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by GS-9857.	Hepatitis virus infection [1E50-1E51]	[53]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Atorvastatin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[34]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Atorvastatin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[54]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Atorvastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Saquinavir	DMG814N	Major	Decreased metabolism of Atorvastatin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Atorvastatin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[57]
Darunavir	DMN3GCH	Major	Decreased metabolism of Atorvastatin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[44]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[58]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Atorvastatin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[59]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Atorvastatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[49]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Atorvastatin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[60]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Atorvastatin due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[35]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Atorvastatin caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[61]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Atorvastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[37]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Atorvastatin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[37]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Atorvastatin caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[34]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Atorvastatin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Atorvastatin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[35]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Atorvastatin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[34]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Atorvastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[37]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Atorvastatin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[62]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Atorvastatin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[63]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Atorvastatin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[33]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Atorvastatin caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[34]
LGX818	DMNQXV8	Moderate	Increased metabolism of Atorvastatin caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[64]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Atorvastatin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[33]
Danazol	DML8KTN	Major	Decreased metabolism of Atorvastatin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[39]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[65]
Exjade	DMHPRWG	Moderate	Increased metabolism of Atorvastatin caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[34]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Atorvastatin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Atorvastatin caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Atorvastatin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[37]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Atorvastatin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[39]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Atorvastatin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[37]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Atorvastatin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[37]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Atorvastatin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[66]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Atorvastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[67]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Atorvastatin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[34]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[68]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Atorvastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[37]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Atorvastatin due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[35]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Atorvastatin due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[35]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Atorvastatin due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[35]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Atorvastatin due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[35]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Atorvastatin due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[35]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Atorvastatin due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[35]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Atorvastatin caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[34]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Atorvastatin due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[35]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Atorvastatin and Leflunomide.	Rheumatoid arthritis [FA20]	[49]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Atorvastatin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[37]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Atorvastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[35]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Atorvastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Armodafinil	DMGB035	Minor	Increased metabolism of Atorvastatin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[69]
LEE011	DMMX75K	Moderate	Decreased metabolism of Atorvastatin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Atorvastatin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[70]
Brilinta	DMBR01X	Minor	Decreased metabolism of Atorvastatin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[35]
Liraglutide	DM3FXPS	Minor	Altered absorption of Atorvastatin due to GI dynamics variation caused by Liraglutide.	Type 2 diabetes mellitus [5A11]	[71]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Atorvastatin caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[34]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Atorvastatin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[37]
-----------


⏷ Show the Full List of 107 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Arginine	E00112	6322	Buffering agent; Dispersing agent
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Simethicone	E00575	6433516	Antifoaming agent; Diluent; Water-repelling agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium acetate	E00098	6116	Antimicrobial preservative; Complexing agent
Carbonic acid disodium salt	E00199	10340	Alkalizing agent; Buffering agent; Diluent; Dispersing agent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Tromethamine	E00125	6503	Alkalizing agent; Buffering agent; Emulsifying agent
Water	E00035	962	Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 32 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Atorvastatin 10 mg tablet	10 mg	Oral Tablet	Oral
Atorvastatin 20 mg tablet	20 mg	Oral Tablet	Oral
Atorvastatin 40 mg tablet	40 mg	Oral Tablet	Oral
Atorvastatin 80 mg tablet	80 mg	Oral Tablet	Oral
Atorvastatin Calcium eq 10mg base tablet	eq 10mg base	Tablet	Oral
Atorvastatin Calcium eq 2.5mg base tablet	eq 2.5mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Atorvastatin FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
4	ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
5	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
9	Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
10	Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
11	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
12	Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
13	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
14	Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
15	FDA Drug Development and Drug Interactions
16	Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
19	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
20	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
21	Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
22	UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
23	Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
24	Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
25	Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011 Feb 3;146(3):319-25. doi: 10.1016/j.ijcard.2009.07.002. Epub 2009 Aug 3.
26	Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
27	Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol. 2002 Jul;17(7):540-3. doi: 10.1007/s00467-002-0860-z. Epub 2002 May 25.
28	Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
29	Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
30	RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
31	Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
32	Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
33	Cerner Multum, Inc. "Australian Product Information.".
34	Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
35	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36	Multum Information Services, Inc. Expert Review Panel.
37	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
38	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
39	Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
40	Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9. [PMID: 11936570]
41	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
42	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
43	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Product Information. Lipitor (atorvastatin). Parke-Davis, Morris Plains, NJ.
45	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
47	Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
48	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
49	Canadian Pharmacists Association.
50	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
51	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
52	Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
53	Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
54	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
55	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
56	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
57	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
58	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
59	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
60	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
61	Product Information. Tekturna (aliskiren). Novartis Pharmaceuticals, East Hanover, NJ.
62	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
63	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
64	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
65	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
66	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
67	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
68	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
69	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
70	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71	Product Information. Victoza (liraglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.